Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic activation of the inflammatory cascade against yet unknown environmental factors that trigger the disease. IBD therapy aims at improving the quality of life and reducing the risk of disease-related complications to avoid the need for surgery. There is no specific cure for IBDs, and the focus of therapy is supportive measures and use of anti-inflammatory and immunosuppressive drugs. Glucocorticoids (GCs) are powerful anti-inflammatory and immunomodulatory agents used to treat many acute and chronic inflammatory diseases. GCs remain basic treatment for moderate-to-severe IBD, but their use is limited by several important adverse drug effects. Topical administration of a second-generation of GCs, such as budesonide and beclomethasone dipropionate (BDP), represents a valid alternative to use of older, systemic GCs. Administration of second-generation GCs shows promisingly high topical activity and less systemic toxicity, but maintenance therapy with these new GCs in IBD patients is associated with multiple adverse effects. In this review, we make a comparative analysis of the efficacy of first-generation and second-generation GCs in IBD treatment. Unraveling GC biology at the molecular level to uncouple their clinical benefits from detrimental effects is important. One approach is to consider new GC mediators, such as glucocorticoid-induced leucine zipper, which may have similar anti-inflammatory properties, but avoids the side effects of GCs. This in-depth analysis can help to improve the development and the clinical outcomes of GC therapies in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 1×
“mutations in IBD susceptibility loci including those of STAT3, TYK2, JAK2, CARD9 and IL10RA genes) (27), as a cause or consequence to an imbalance in commensal microbes, or if different environmental factors favor dysbiosis; poor hygiene (28), unbalanced diets (29), smoking, and stress (27).”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346 · cited 1×
“However, as a second-generation GC with low systemic absorption, it is associated with fewer adverse events than that of first-generation GCs (44, 45).”
BackgroundInflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818 · cited 1×
“They play a key part in regulating solubility, drug aggregation, low bioavailability, poor biodistribution, and reducing side effects (46).”
BackgroundRamamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692
Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R., & Weaver, C. T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415675112 · Cited by 427 · cited 1×
“CD is characterized by an imbalance in the number of Th1 cells (21).”
BackgroundCytokine activation of the HPA axis
DUNN, A. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05426.x · Cited by 352 · cited 1×
“The HPA acts on inflammation by regulating genomic and non-genomic pathways, thereby blocking the activation, migration, and proliferation of immune cells of the innate and adaptive immune system (Figure 1) (4).”
BackgroundCroxtall, J. D., Choudhury, Q., & Flower, R. J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703272 · Cited by 332 · cited 1×
“These are characterized mainly by a short delay of action and often involve generation of intracellular second messengers and various signal-transduction cascades, such as phospholipase activation, modulation of cyclic adenosine monophosphate, protein kinase pathways, and Ca mobilization (12, 13).”
BackgroundBereshchenko, O., Coppo, M., Bruscoli, S., Biagioli, M., Cimino, M., Frammartino, T., Sorcini, D., Venanzi, A., Di Sante, M., & Riccardi, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.004 · Cited by 131
Self-citation
Cited by
The enteric nervous system relays psychological stress to intestinal inflammation
Schneider, K. M., Blank, N., Alvarez, Y., Thum, K., Lundgren, P., Litichevskiy, L., Sleeman, M., Bahnsen, K., Kim, J., Kardo, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.001 · Cited by 344
Sic, A., Cvetkovic, K., Manchanda, E., & Knezevic, N. N. (2024) · Diseases · doi:10.3390/diseases12090220 · Cited by 65
“Monitoring the biomarkers of inflammation and cortisol activity can aid in adjusting dosages and selecting the most appropriate analog for individual patients [137].”
Background
Metadata
- Authors
- Bruscoli, S., Febo, M., Riccardi, C., & Migliorati, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-06-03
- Volume
- 12
- Pages
- 691480-691480
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3171373099
- Cited by
- 215
- References
- 11
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.